Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women

详细信息    查看全文

• 作者：Daniel Murkes ; Peter Conner ; Karin Leifl ; Edneia Tani ; Aude Beliard ; Eva Lundströ ; m ; Gunnar Sö ; derqvist
• 关键词：Percutaneous estradiol ; micronized progesterone ; HT ; proliferation ; bcl-2 protein ; normal breast tissue
• 刊名：Fertility and Sterility
• 出版年：2011
• 出版时间：1 March 2011
• 年：2011
• 卷：95
• 期：3
• 页码：1188-1191
• 全文大小：381 K

文摘

In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E₂ gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate induced a highly significant increase in breast cell proliferation in contrast to percutaneous E₂–oral P with a difference between therapies approaching significance, the former therapy has a marked impact on the breast whereas natural percutaneous E₂–oral micronized P has not.